Respiratory Syncytial Virus Vaccines

BOSTON — There are a handful of “novel and important” treatments that primary care providers should be aware of this year, according to a speaker.

The monoclonal antibody nirsevimab is 90% effective at preventing respiratory syncytial virus hospitalization in infants, according to research published in MMWR.

Many health care workers, including primary care providers, may have lingering questions surrounding the new respiratory syncytial virus vaccines for older adults.

Major vaccine developments in 2023 included the approvals of the first two vaccines against respiratory syncytial virus, the first chikungunya vaccine, a new vaccine against malaria, and a move to new monovalent COVID-19 vaccines.

On Dec. 14, the CDC issued an urgent warning calling for health care providers to increase vaccination coverage for COVID-19, influenza and respiratory syncytial virus.

The CDC has issued a health advisory to physicians in the United States about clade I mpox virus, which is more transmissible than the clade IIb mpox virus behind last year’s global outbreak.

Moderna’s messenger RNA-based respiratory syncytial virus vaccine is safe and effective for older adults, according to phase 3 trial data.

An intranasal COVID-19 vaccine candidate, CoviLiv, induced a robust immune response, according to a presentation at IDWeek. Researchers plan to test multiple dose levels and observe participants for 2 months after its administration.